Gene editing and CRISPR in the clinic: current and future perspectives
Tóm tắt
Genome editing technologies, particularly those based on zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR (clustered regularly interspaced short palindromic repeat DNA sequences)/Cas9 are rapidly progressing into clinical trials. Most clinical use of CRISPR to date has focused on ex vivo gene editing of cells followed by their re-introduction back into the patient. The ex vivo editing approach is highly effective for many disease states, including cancers and sickle cell disease, but ideally genome editing would also be applied to diseases which require cell modification in vivo. However, in vivo use of CRISPR technologies can be confounded by problems such as off-target editing, inefficient or off-target delivery, and stimulation of counterproductive immune responses. Current research addressing these issues may provide new opportunities for use of CRISPR in the clinical space. In this review, we examine the current status and scientific basis of clinical trials featuring ZFNs, TALENs, and CRISPR-based genome editing, the known limitations of CRISPR use in humans, and the rapidly developing CRISPR engineering space that should lay the groundwork for further translation to clinical application.
Từ khóa
Tài liệu tham khảo
Lander, 2001, Initial sequencing and analysis of the human genome, Nature, 409, 860, 10.1038/35057062
International HapMap Consortium, 2003, The International HapMap Project, Nature, 426, 789, 10.1038/nature02168
Sayers, 2019, Database resources of the National Center for Biotechnology Information, Nucleic Acids Res., 47, D23, 10.1093/nar/gky1069
Wellcome Trust Case Control Consortium, 2007, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature, 447, 661, 10.1038/nature05911
Visscher, 2017, 10 years of GWAS discovery: biology, function, and translation, Am. J. Hum. Genet., 101, 5, 10.1016/j.ajhg.2017.06.005
Gaj, 2013, ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering, Trends Biotechnol., 31, 397, 10.1016/j.tibtech.2013.04.004
Carroll, 2011, Genome engineering with zinc-finger nucleases, Genetics, 188, 773, 10.1534/genetics.111.131433
Joung, 2013, TALENs: a widely applicable technology for targeted genome editing, Nat. Rev. Mol. Cell Biol., 14, 49, 10.1038/nrm3486
Mojica, 2000, Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria, Mol. Microbiol., 36, 244, 10.1046/j.1365-2958.2000.01838.x
Barrangou, 2007, CRISPR provides acquired resistance against viruses in prokaryotes, Science, 315, 1709, 10.1126/science.1138140
Adli, 2018, The CRISPR tool kit for genome editing and beyond, Nat. Commun., 9, 1911, 10.1038/s41467-018-04252-2
Sternberg, 2015, Expanding the biologist’s toolkit with CRISPR-Cas9, Mol. Cell, 58, 568, 10.1016/j.molcel.2015.02.032
Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033
Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143
Wiedenheft, 2012, RNA-guided genetic silencing systems in bacteria and archaea, Nature, 482, 331, 10.1038/nature10886
Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337, 816, 10.1126/science.1225829
Lino, 2018, Delivering CRISPR: a review of the challenges and approaches, Drug Deliv., 25, 1234, 10.1080/10717544.2018.1474964
Hütter, 2009, Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation, N. Engl. J. Med., 360, 692, 10.1056/NEJMoa0802905
Yukl, 2013, Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin Patient, PLoS Pathog., 9, e1003347, 10.1371/journal.ppat.1003347
Perez, 2008, Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases, Nat. Biotechnol., 26, 808, 10.1038/nbt1410
Tebas, 2014, Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV, N. Engl. J. Med., 370, 901, 10.1056/NEJMoa1300662
Zhang, 2017, Programmable base editing of zebrafish genome using a modified CRISPR-Cas9 system, Nat. Commun., 8, 118, 10.1038/s41467-017-00175-6
Ye, 2014, Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection, Proc. Natl Acad. Sci. U.S.A., 111, 9591, 10.1073/pnas.1407473111
Allen, 2018, Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection, Front. Microbiol., 9, 2940, 10.3389/fmicb.2018.02940
Khalili, 2017, Novel AIDS therapies based on gene editing, Cell. Mol. Life Sci., 74, 2439, 10.1007/s00018-017-2479-z
Didigu, 2014, Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD41 T cells from HIV-1 infection, Blood, 123, 61, 10.1182/blood-2013-08-521229
Liu, 2017, Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection, Cell Biosci., 7, 47, 10.1186/s13578-017-0174-2
Yu, 2018, Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance to both X4- and R5-tropic human immunodeficiency virus type 1 infection, Hum. Gene Ther., 29, 51, 10.1089/hum.2017.032
Kaminski, 2016, Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study, Gene Ther., 23, 690, 10.1038/gt.2016.41
Dash, 2019, Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice, Nat. Commun., 10, 2753, 10.1038/s41467-019-10366-y
Naidoo, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol., 26, 2375, 10.1093/annonc/mdv383
Gong, 2018, Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations, J. Immunother. Cancer, 6, 8, 10.1186/s40425-018-0316-z
Lu, 2018, A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression [abstract], Proceedings of the American Association for Cancer Research Annual Meeting 2018, 10.1158/1538-7445.AM2018-CT133
Lu, 2018, A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer, J. Clin. Oncol., 36, 3050, 10.1200/JCO.2018.36.15_suppl.3050
Rohaan, 2018, Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option, J. Immunother. Cancer, 6, 102, 10.1186/s40425-018-0391-1
Geukes Foppen, 2015, Tumor-infiltrating lymphocytes for the treatment of metastatic cancer, Mol. Oncol., 9, 1918, 10.1016/j.molonc.2015.10.018
Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253
Palmer, 2015, Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance, J. Exp. Med., 212, 2095, 10.1084/jem.20150304
Beane, 2015, Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma, Mol. Ther., 23, 1380, 10.1038/mt.2015.71
Barrett, 2015, Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street, J. Immunol., 195, 755, 10.4049/jimmunol.1500751
Fesnak, 2016, Engineered T cells: the promise and challenges of cancer immunotherapy, Nat. Rev. Cancer, 16, 566, 10.1038/nrc.2016.97
Garrido, 2016, The urgent need to recover MHC class I in cancers for effective immunotherapy, Curr. Opin. Immunol., 39, 44, 10.1016/j.coi.2015.12.007
Karpanen, 2015, T-cell receptor gene therapy e ready to go viral?, Mol. Oncol., 9, 2019, 10.1016/j.molonc.2015.10.006
Thomas, 2018, NY-ESO-1 based immunotherapy of cancer: current perspectives, Front. Immunol., 9, 947, 10.3389/fimmu.2018.00947
Milone, 2018, The pharmacology of T cell therapies, Mol. Ther. Methods Clin. Dev., 8, 210, 10.1016/j.omtm.2018.01.010
Zhao, 2019, Clinical trials of dual-targeted CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lumphoid leukemia, J. Hematol. Oncol., 12, 17, 10.1186/s13045-019-0705-x
Zheng, 2018, Highly efficient base editing in bacteria using a Cas9-cytidine deaminase fusion, Commun. Biol., 1, 32, 10.1038/s42003-018-0035-5
Jin, 2016, Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer, EMBO Mol. Med., 8, 702, 10.15252/emmm.201505869
Hacein-Bey-Abina, 2008, Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, J. Clin. Invest., 118, 3132, 10.1172/JCI35700
Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547
Avedillo Díez, 2011, Development of novel efficient SIN vectors with improved safety features for Wiskott Aldrich syndrome stem cell based gene therapy, Mol. Pharm., 8, 1525, 10.1021/mp200132u
Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat. Med., 12, 401, 10.1038/nm1393
Modlich, 2009, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors, Mol. Ther., 17, 1919, 10.1038/mt.2009.179
Osborn, 2016, Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases, Mol. Ther., 24, 570, 10.1038/mt.2015.197
Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405
Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci. Transl. Med., 9, eaaj2013, 10.1126/scitranslmed.aaj2013
Roth, 2018, Reprogramming human T cell function and specificity with non-viral genome targeting, Nature, 559, 405, 10.1038/s41586-018-0326-5
Smith, 2018, Posttransplant chimeric antigen receptor therapy, Blood, 131, 1045, 10.1182/blood-2017-08-752121
Gaudelli, 2017, Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage, Nature, 551, 464, 10.1038/nature24644
Komor, 2017, Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C: G-to-T: a base editors with higher efficiency and product purity, Sci Adv, 3, eaao4774, 10.1126/sciadv.aao4774
Ren, 2016, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin. Cancer Res., 23, 2255, 10.1158/1078-0432.CCR-16-1300
Poirot, 2015, Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies, Cancer Res., 75, 3853, 10.1158/0008-5472.CAN-14-3321
Gomes-Silva, 2017, CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies, Blood, 130, 285, 10.1182/blood-2017-01-761320
Haanen, 2017, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 28, iv119, 10.1093/annonc/mdx225
Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245
Locke, 2017, Phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), Blood, 130, 2826, 10.1182/blood.V130.Suppl_1.1547.1547
Jacobson, 2019, End of phase 1 results from Zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma, Biol. Blood Marrow Transplant., 25, S173, 10.1016/j.bbmt.2018.12.314
Hu, 2019, CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelintargeted CAR T cell effector functions, Cancer Immunol. Immunother., 68, 365077, 10.1007/s00262-018-2281-2
Rupp, 2017, CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells, Sci. Rep., 7, 737, 10.1038/s41598-017-00462-8
Cavazzana-Calvo, 2010, Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia, Nature, 467, 318, 10.1038/nature09328
Cai, 2018, A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease, Stem Cells Transl. Med., 7, 87, 10.1002/sctm.17-0066
Ou, 2016, The combination of CRISPR/Cas9 and iPSC technologies in the gene therapy of human β-thalassemia in mice, Sci. Rep., 6, 32463, 10.1038/srep32463
Wattanapanitch, 2018, One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system, Stem Cell Res. Ther., 9, 46, 10.1186/s13287-018-0779-3
Xie, 2014, Seamless gene correction of b-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac, Genome Res., 24, 1526, 10.1101/gr.173427.114
Patsali, 2019, Correction of IVS I-110 (G>A) b-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant progenitor cells, Haematologica, 104, e497, 10.3324/haematol.2018.215178
Wienert, 2018, Wake-up sleepy gene: reactivating fetal globin for β-hemoglobinopathies, Trends Genet., 34, 927, 10.1016/j.tig.2018.09.004
Ye, 2016, Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia, Proc. Natl. Acad. Sci. U.S.A., 113, 10661, 10.1073/pnas.1612075113
Bjurström, 2016, Reactivating fetal hemoglobin expression in human adult erythroblasts through BCL11A knockdown using targeted endonucleases, Mol. Ther. Nucleic Acids, 5, e351, 10.1038/mtna.2016.52
Chang, 2017, Long-term engraftment and fetal globin induction upon BCL11A gene editing inbone-marrow-derived CD34+ hematopoietic stem and progenitor cells, Mol. Ther. Methods Clin. Dev., 4, 137, 10.1016/j.omtm.2016.12.009
Zhen, 2017, Oncogenic human papillomavirus: application of CRISPR/Cas9 therapeutic strategies for cervical cancer, Cell. Physiol. Biochem., 44, 2455, 10.1159/000486168
Ren, 2019, An effective and biocompatible polyethylenimine based vaginal suppository for gene delivery, Nanomedicine, 20, 101994, 10.1016/j.nano.2019.03.016
Ding, 2014, Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells, Clin. Cancer Res., 20, 6495, 10.1158/1078-0432.CCR-14-0250
Hu, 2015, TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy, J. Clin. Invest., 125, 425, 10.1172/JCI78206
Lao, 2018, HPV oncogene manipulation using nonvirally delivered CRISPR/Cas9 or Natronobacterium gregoryi argonaute, Adv. Sci., 5, 1700540, 10.1002/advs.201700540
Hsu, 2018, Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo, Future Virol., 13, 475, 10.2217/fvl-2018-0010
Yoshiba, 2019, CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6, Oncol. Lett., 17, 2197
Li, 2011, In vivo genome editing restores haemostasis in a mouse model of haemophilia, Nature, 475, 217, 10.1038/nature10177
Anguela, 2013, Robust ZFN-mediated genome editing in adult hemophilic mice, Blood, 122, 3283, 10.1182/blood-2013-04-497354
Sharma, 2015, In vivo genome editing of the albumin locus as a platform for protein replacement therapy, Blood, 126, 1777, 10.1182/blood-2014-12-615492
Zong, 2017, Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion, Nat. Biotechnol., 35, 438, 10.1038/nbt.3811
Sivalingam, 2016, Multidimensional genome-wide analyses show accurate FVIII integration by ZFN in primary human cells, Mol. Ther., 24, 607, 10.1038/mt.2015.223
Ou, 2019, ZFN-mediated in vivo genome editing corrects murine Hurler Syndrome, Mol. Ther., 27, 178, 10.1016/j.ymthe.2018.10.018
Laoharawee, 2018, Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing, Mol. Ther., 26, 1127, 10.1016/j.ymthe.2018.03.002
Sheridan, 2018, Sangamo’s landmark genome editing trial gets mixed reception, Nat. Biotechnol., 36, 907, 10.1038/nbt1018-907
Maeder, 2019, Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10, Nat. Med., 25, 229, 10.1038/s41591-018-0327-9
Dominguez, 2016, Beyond editing: repurposing CRISPR–Cas9 for precision genome regulation and interrogation, Nat. Rev. Mol. Cell Biol., 17, 5, 10.1038/nrm.2015.2
Thakore, 2016, Editing the epigenome: technologies for programmable transcriptional modulation and epigenetic regulation, Nat. Methods, 13, 127, 10.1038/nmeth.3733
Hong, 2018, CRISPR in personalized medicine: industry perspectives in gene editing, Semin. Perinatol., 42, 501, 10.1053/j.semperi.2018.09.008
Booth, 2016, Treating immunodeficiency through HSC Gene iherapy, Trends Mol. Med., 22, 317, 10.1016/j.molmed.2016.02.002
Genovese, 2014, Targeted genome editing in human repopulating haematopoietic stem cells, Nature, 510, 235, 10.1038/nature13420
Pavel-Dinu, 2019, Gene correction for SCID-X1 in long-term hematopoietic stem cells, Nat. Commun., 10, 10.1038/s41467-019-13620-5
Schiroli, 2017, Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1, Sci. Transl. Med., 9, eean0820, 10.1126/scitranslmed.aan0820
De Ravin, 2017, CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease, Sci. Transl. Med., 9, eaah3480, 10.1126/scitranslmed.aah3480
De Ravin, 2016, Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease, Nat. Biotechnol., 34, 424, 10.1038/nbt.3513
Dreyer, 2015, TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells, Biomaterials, 69, 191, 10.1016/j.biomaterials.2015.07.057
Flynn, 2015, CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells, Exp. Hematol., 43, 838, 10.1016/j.exphem.2015.06.002
Merling, 2015, An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease, Mol. Ther., 23, 147, 10.1038/mt.2014.195
Sürün, 2018, High efficiency gene correction in hematopoietic cells by donor-template-free CRISPR/Cas9 genome editing, Mol. Ther. Nucleic Acids, 10, 1, 10.1016/j.omtn.2017.11.001
Gutierrez-Guerrero, 2018, Comparison of zinc finger nucleases versus CRISPR-specific nucleases for genome editing of the Wiskott-Aldrich Syndrome locus, Hum. Gene Ther., 29, 366, 10.1089/hum.2017.047
Rodrigues, 2018, Pharmaceutical development of AAV-based gene therapy products for the eye, Pharm. Res., 36, 29, 10.1007/s11095-018-2554-7
Trapani, 2018, Seeing the light after 25 years of retinal gene therapy, Trends Mol. Med., 24, 669, 10.1016/j.molmed.2018.06.006
McCullough, 2019, Somatic gene editing of GUCY2D by AAV-CRISPR/Cas9 alters retinal structure and function in mouse and macaque, Hum. Gene Ther., 30, 571, 10.1089/hum.2018.193
Xu, 2018, Translation of CRISPR genome surgery to the bedside for retinal diseases, Front. Cell Dev. Biol., 6, 46, 10.3389/fcell.2018.00046
Yu, 2018, In vivo applications of CRISPR-based genome editing in the retina, Front. Cell Dev. Biol., 6, 53, 10.3389/fcell.2018.00053
Fuster-García, 2017, USH2A gene editing using the CRISPR system, Mol. Ther. Nucleic Acids, 8, 529, 10.1016/j.omtn.2017.08.003
Mianné, 2016, Correction of the auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair, Genome Med., 8, 16, 10.1186/s13073-016-0273-4
Gao, 2018, Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents, Nature, 553, 217, 10.1038/nature25164
Zuris, 2015, Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo, Nat. Biotechnol., 33, 73, 10.1038/nbt.3081
Stephens, 2018, Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9, Gene Ther., 25, 139, 10.1038/s41434-018-0003-1
Bjursell, 2018, Therapeutic genome editing with CRISPR/Cas9 in a humanized mouse model ameliorates α1-antitrypsin deficiency phenotype, EBioMedicine, 29, 104, 10.1016/j.ebiom.2018.02.015
Shen, 2018, Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice, Hum. Gene Ther., 29, 861, 10.1089/hum.2017.227
Song, 2018, In vivo genome editing partially restores alpha 1-antitrypsin in a murine model of AAT deficiency, Hum. Gene Ther., 29, 853, 10.1089/hum.2017.225
Finn, 2018, A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing, Cell Rep., 22, 2227, 10.1016/j.celrep.2018.02.014
Yang, 2018, The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA, Virus Res., 244, 304, 10.1016/j.virusres.2017.06.010
Gilani, 2018, Theimplication ofCRISPR/Cas9genomeediting technology in combating human oncoviruses, J. Med. Virol., 91, 1, 10.1002/jmv.25292
Moyo, 2017, Advances with using CRISPR/Cas-mediated gene editing to treatinfections with hepatitis B virus and hepatitis C virus, Virus Res., 244, 311, 10.1016/j.virusres.2017.01.003
Paschon, 2020, CRISPR, Prime Editing, Optogenetics, and DREADDs: new therapeutic approaches provided by emerging technologies in the treatment of spinal cord injury, Mol. Neurobiol., 57, 2085, 10.1007/s12035-019-01861-w
Sondhi, 2017, Genetic modification of the lung directed toward treatment of human disease, Hum. Gene Ther., 28, 3, 10.1089/hum.2016.152
Villate-Beitia, 2017, Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis, Drug Dev. Ind. Pharm., 43, 1071, 10.1080/03639045.2017.1298122
Xia, 2018, Overcoming the undesirable CRISPR-Cas9 expression in gene correction, Mol. Ther. Nucleic Acids, 13, 699, 10.1016/j.omtn.2018.10.015
Ruan, 2019, Efficient gene editing at major CFTR mutation loci, Mol. Ther. Nucleic Acids, 16, 73, 10.1016/j.omtn.2019.02.006
Sanz, 2017, Cas9/gRNA targeted excision of cystic fibrosiscausing deep-intronic splicing mutations restores normal splicing of CFTR mRNA, PLoS ONE, 12, e0184009, 10.1371/journal.pone.0184009
Bednarski, 2016, Targeted integration of a super-exon into the CFTR locus leads to functional correction of a cystic fibrosis cell line model, PLoS ONE, 11, e0161072, 10.1371/journal.pone.0161072
Schwank, 2013, Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients, Cell Stem Cell, 13, 653, 10.1016/j.stem.2013.11.002
Crane, 2015, Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells, Stem Cell Rep., 4, 569, 10.1016/j.stemcr.2015.02.005
Firth, 2015, Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient iPSCs, Cell Rep., 12, 1385, 10.1016/j.celrep.2015.07.062
Lee, 2012, Correction of the ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator gene by zinc-finger nuclease homology-directed repair, BioResearch, 1, 99, 10.1089/biores.2012.0218
Min, 2019, CRISPR correction of Duchenne muscular dystrophy, Annu. Rev. Med., 70, 239, 10.1146/annurev-med-081117-010451
Amoasii, 2018, Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy, Science, 362, 86, 10.1126/science.aau1549
Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3
Yang, 2019, The CRIPSR/Cas gene-editing system-an immature but useful toolkit for experimental and clinical medicine, Anim. Model Exp. Med., 2, 5, 10.1002/ame2.12061
Ormond, 2017, Human germline genome editing, Am. J. Hum. Genet., 101, 167, 10.1016/j.ajhg.2017.06.012
Long, 2014, Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA, Science, 345, 1184, 10.1126/science.1254445
German, 2019, Therapeutic genome editing in cardiovascular diseases, J. Am. Coll. Cardiol. Basic Trans. Sci., 4, 122
Ma, 2017, Correction of a pathogenic gene mutation in human embryos, Nature, 548, 413, 10.1038/nature23305
Tang, 2017, CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein, Mol. Genet. Genomics, 292, 252, 10.1007/s00438-017-1299-z
Liang, 2015, CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes, Protein Cell, 6, 363, 10.1007/s13238-015-0153-5
Fogarty, 2017, Genome editing reveals a role for OCT4 in human embryogenesis, Nature, 550, 67, 10.1038/nature24033
Greely, 2019, CRISPR’d babies: human germline genome editing in the ‘He Jiankui affair’, J. Law Biosci., 6, 111, 10.1093/jlb/lsz010
Ranisch, 2020, Germline genome editing versus preimplantation genetic diagnosis: Is there a case in favour of germline interventions?, Bioethics, 34, 60, 10.1111/bioe.12635
Cross, 2017, CRISPR’s breakthrough problem, Chem. Eng. News, 95, 28
Glass, 2018, Engineering the delivery system for CRISPR-based genome Editing, Trends Biotechnol., 36, 173, 10.1016/j.tibtech.2017.11.006
Chew, 2018, Immunity to CRISPR Cas9 and Cas12a therapeutics, Wiley Interdiscip. Rev. Syst. Biol. Med., 10, e1408, 10.1002/wsbm.1408
Barbalat, 2011, Nucleic acid recognition by the innate immune system, Annu. Rev. Immunol., 29, 185, 10.1146/annurev-immunol-031210-101340
Kim, 2018, CRISPR RNAs trigger innate immune responses in human cells, Genome Res., 28, 367, 10.1101/gr.231936.117
Wienert, 2018, In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway, PLoS Biol., 16, e2005840, 10.1371/journal.pbio.2005840
Charlesworth, 2019, Identification of preexisting adaptive immunity to Cas9 proteins in humans, Nat. Med., 25, 249, 10.1038/s41591-018-0326-x
Simhardri, 2018, Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population, Mol. Ther. Methods Clin. Dev., 10, 105, 10.1016/j.omtm.2018.06.006
Chew, 2016, A multifunctional AAV–CRISPR–Cas9 and its host response, Nat. Methods, 13, 868, 10.1038/nmeth.3993
Wagner, 2019, High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population, Nat. Med., 25, 242, 10.1038/s41591-018-0204-6
Zhang, 2015, Off-target effects in CRISPR/Cas9-mediated genome engineering, Mol. Ther. Nucleic Acids, 4, e264, 10.1038/mtna.2015.37
Florea, 2011, Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects, Cancers (Basel), 3, 1351, 10.3390/cancers3011351
Gkazi, 2019, Quantifying CRISPR off-target effects, Emerg. Top. Life Sci., 3, 327, 10.1042/ETLS20180146
Akcakaya, 2018, In vivo CRISPR editing with no detectable genome-wide off-target mutations, Nature, 561, 416, 10.1038/s41586-018-0500-9
Wienert, 2019, Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq, Science, 364, 286, 10.1126/science.aav9023
Harewood, 2014, The impact of chromosomal rearrangements on regulation of gene expression, Hum. Mol. Genet., 23, R76, 10.1093/hmg/ddu278
Hasty, 2014, Chromosomal rearrangements in cancer detection and potential causal mechanisms, Mol. Cell. Oncol., 1, e29904, 10.4161/mco.29904
Giannoukos, 2018, UDiTaS, a genome editing detection method for indels and genome rearrangements, BMC Genomics, 19, 212, 10.1186/s12864-018-4561-9
Jung, 2017, Massively parallel biophysical analysis of CRISPR-Cas complexes on next generation sequencing chips, Cell, 170, 35, 10.1016/j.cell.2017.05.044
Smits, 2019, Biological plasticity rescues target activity in CRISPR knock outs, Nat. Methods., 16, 1087, 10.1038/s41592-019-0614-5
Ihry, 2018, p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells, Nat. Med., 24, 939, 10.1038/s41591-018-0050-6
Haapaniemi, 2018, CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response, Nat. Med., 24, 927, 10.1038/s41591-018-0049-z
Newton, 2019, DNA stretching induces Cas9 off-target activity, Nat. Struct. Mol. Biol., 26, 185, 10.1038/s41594-019-0188-z
Aryal, 2018, CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo, Cell Death. Dis., 9, 1099, 10.1038/s41419-018-1146-0
Yamada, 2017, Crystal structure of the minimal Cas9 from Campylobacter jejuni reveals the molecular diversity in the CRISPR-Cas9 systems, Mol. Cell, 65, 1109, 10.1016/j.molcel.2017.02.007
Jiang, 2017, CRISPR-Cas9 structures and mechanisms, Annu. Rev. Biophys., 46, 505, 10.1146/annurev-biophys-062215-010822
Nishimasu, 2015, Crystal structure of Staphylococcus aureus Cas9, Cell, 162, 1113, 10.1016/j.cell.2015.08.007
Nishimasu, 2014, Crystal structure of Cas9 in complex with guide RNA and target DNA, Cell, 156, 935, 10.1016/j.cell.2014.02.001
Yang, 2018, The conformational dynamics of Cas9 governing DNA cleavage are revealed by single-molecule FRET, Cell Rep., 22, 372, 10.1016/j.celrep.2017.12.048
Slaymaker, 2016, Rationally engineered Cas9 nucleases with improved specificity, Science, 351, 84, 10.1126/science.aad5227
Kleinstiver, 2016, High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects, Nature, 529, 490, 10.1038/nature16526
Chen, 2017, Enhanced proofreading governs CRISPR-Cas9 targeting accuracy, Nature, 550, 407, 10.1038/nature24268
Casini, 2018, A highly specific SpCas9 variant is identified by in vivo screening in yeast, Nat. Biotechnol., 36, 265, 10.1038/nbt.4066
Vakulskas, 2018, A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells, Nat. Med., 24, 1216, 10.1038/s41591-018-0137-0
Hu, 2018, Evolved Cas9 variants with broad PAM compatibility and high DNA specificity, Nature, 556, 57, 10.1038/nature26155
Tsai, 2014, Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing, Nat. Biotechnol., 32, 569, 10.1038/nbt.2908
Guilinger, 2014, Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification, Nat. Biotechnol., 32, 577, 10.1038/nbt.2909
Mali, 2013, CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering, Nat. Biotechnol., 31, 833, 10.1038/nbt.2675
Ran, 2013, Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity, Cell, 154, 1380, 10.1016/j.cell.2013.08.021
Fu, 2014, Improving CRISPR-Cas nuclease specificity using truncated guide RNAs, Nat. Biotechnol., 32, 279, 10.1038/nbt.2808
Bolukbasi, 2015, DNA-binding-domain fusions enhance the targeting range and precision of Cas9, Nat. Methods, 12, 1150, 10.1038/nmeth.3624
Maji, 2017, Multidimensional chemical control of CRISPR-Cas9, Nat. Chem. Biol., 13, 9, 10.1038/nchembio.2224
Xu, 2015, Sequence determinants of improved CRISPR sgRNA design, Genome Res., 25, 1147, 10.1101/gr.191452.115
Wu, 2014, Target specificity of the CRISPR-Cas9 system, Quant. Biol., 2, 59, 10.1007/s40484-014-0030-x
Cui, 2018, Review of CRISPR/Cas9 sgRNA design tools, Interdiscip. Sci., 10, 455, 10.1007/s12539-018-0298-z
Hendel, 2015, Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells, Nat. Biotechnol., 33, 985, 10.1038/nbt.3290
Yin, 2017, Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing, Nat. Biotechnol., 35, 1179, 10.1038/nbt.4005
Ryan, 2018, Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs, Nucleic Acids Res., 46, 792, 10.1093/nar/gkx1199
Mir, 2018, Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing, Nat. Commun., 9, 2641, 10.1038/s41467-018-05073-z
O’Reilly, 2019, Extensive CRISPR RNA modification reveals chemical compatibility and structure-activity relationships for Cas9 biochemical activity, Nucleic Acids Res., 47, 546
Kocak, 2019, Increasing the specificity of CRISPR systems with engineered RNA secondary structures, Nat. Biotechnol., 37, 657, 10.1038/s41587-019-0095-1
Strecker, 2019, RNA-guided DNA insertion with CRISPR-associated transposases, Science, 365, 48, 10.1126/science.aax9181
Klompe, 2019, Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration, Nature, 571, 219, 10.1038/s41586-019-1323-z
Guirouilh-Barbat, 2004, Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells, Mol. Cell, 14, 611, 10.1016/j.molcel.2004.05.008
Aird, 2018, Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template, Commun. Biol., 1, 54, 10.1038/s42003-018-0054-2
Lin, 2014, Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery, Elife, 3, e04766, 10.7554/eLife.04766
Komor, 2016, Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage, Nature, 533, 420, 10.1038/nature17946
Kim, 2017, Highly efficient RNA-guided base editing in mouse embryos, Nat. Biotechnol., 35, 435, 10.1038/nbt.3816
Ma, 2018, Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats, Cell Discov., 4, 39, 10.1038/s41421-018-0047-9
Yeh, 2018, In vivo base editing of post-mitotic sensory cells, Nat. Commun., 9, 2184, 10.1038/s41467-018-04580-3
Lee, 2018, Targeting fidelity of adenine and cytosine base editors in mouse embryos, Nat. Commun., 9, 4804, 10.1038/s41467-018-07322-7
Tan, 2019, Engineering of high-precision base editors for site-specific single nucleotide replacement, Nat. Commun., 10, 439, 10.1038/s41467-018-08034-8
Liang, 2019, Genome-wide profiling of adenine base editor specificity by EndoV-seq, Nat. Commun., 10, 67, 10.1038/s41467-018-07988-z
Zafra, 2018, Optimized base editors enable efficient editing in cells, organoids and mice, Nat. Biotechnol., 36, 888, 10.1038/nbt.4194
Thuronyi, 2019, Continuous evolution of base editors with expanded target compatibility and improved activity, Nat. Biotechnol., 37, 1070, 10.1038/s41587-019-0193-0
Liu, 2018, Intrinsic nucleotide preference of diversifying base editors guides antibody ex vivo affinity maturation, Cell Rep., 25, 884, 10.1016/j.celrep.2018.09.090
Zuo, 2019, Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos, Science, 364, 289, 10.1126/science.aav9973
Jin, 2019, Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice, Science, 364, 292, 10.1126/science.aaw7166
Grunewald, 2019, Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors, Nature, 569, 433, 10.1038/s41586-019-1161-z
Kim, 2019, Genome-wide target specificity of CRISPR RNA-guided adenine base editors, Nat. Biotechnol., 37, 430, 10.1038/s41587-019-0050-1
Terns, 2018, CRISPR-based technologies: impact of RNA-targeting systems, Mol. Cell, 72, 404, 10.1016/j.molcel.2018.09.018
O'Connell, 2014, Programmable RNA recognition and cleavage by CRISPR/Cas9, Nature, 516, 263, 10.1038/nature13769
Nelles, 2016, Programmable RNA tracking in live cells with CRISPR/Cas9, Cell, 165, 488, 10.1016/j.cell.2016.02.054
Liu, 2016, Targeting cellular mRNAs translation by CRISPR-Cas9, Sci. Rep., 6, 29652, 10.1038/srep29652
Batra, 2017, Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9, Cell, 170, 899e10, 10.1016/j.cell.2017.07.010
Dugar, 2018, CRISPR RNA-Dependent Binding and Cleavage of Endogenous RNAs by the Campylobacter jejuni Cas9, Mol. Cell, 69, 893e7, 10.1016/j.molcel.2018.01.032
Price, 2015, Cas9-mediated targeting of viral RNA in eukaryotic cells, Proc. Natl. Acad. Sci. U. S. A., 112, 6164, 10.1073/pnas.1422340112
Rousseau, 2018, Programmable RNA Cleavage and Recognition by a Natural CRISPR-Cas9 System from Neisseria meningitidis, Mol. Cell, 69, 906e4, 10.1016/j.molcel.2018.01.025
Sampson, 2013, A CRISPR/Cas system mediates bacterial innate immune evasion and virulence, Nature, 497, 254, 10.1038/nature12048
Abudayyeh, 2016, C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector, Science, 353, aaf5573, 10.1126/science.aaf5573
Konermann, 2018, Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors, Cell, 173, 665, 10.1016/j.cell.2018.02.033
Qi, 2013, Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression, Cell, 152, 1173, 10.1016/j.cell.2013.02.022
Gilbert, 2013, CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes, Cell, 154, 442, 10.1016/j.cell.2013.06.044
Konermann, 2013, Optical control of mammalian endogenous transcription and epigenetic states, Nature, 500, 472, 10.1038/nature12466
Margolin, 1994, Kruppel-associated boxes are potent transcriptional repression domains, Proc. Natl. Acad. Sci. U. S. A., 91, 4509, 10.1073/pnas.91.10.4509
Lupo, 2013, KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions, Curr. Genomics, 14, 268, 10.2174/13892029113149990002
Gasperini, 2019, A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens, Cell, 176, 1516, 10.1016/j.cell.2019.02.027
Mandegar, 2016, CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs, Cell Stem Cell, 18, 541, 10.1016/j.stem.2016.01.022
Libby, 2018, Spatiotemporal mosaic self-patterning of pluripotent stem cells using CRISPR interference, Elife, 7, 10.7554/eLife.36045
Kearns, 2014, Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells, Development, 141, 219, 10.1242/dev.103341
Zheng, 2018, CRISPR interference-based specific and efficient gene inactivation in the brain, Nat. Neurosci., 21, 447, 10.1038/s41593-018-0077-5
Yeo, 2018, An enhanced CRISPR repressor for targeted mammalian gene regulation, Nat. Methods, 15, 611, 10.1038/s41592-018-0048-5
Maeder, 2013, CRISPR RNA-guided activation of endogenous human genes, Nat. Methods, 10, 977, 10.1038/nmeth.2598
Perez-Pinera, 2013, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, Nat. Methods, 10, 973, 10.1038/nmeth.2600
La Russa, 2015, The new state of the art: Cas9 for gene activation and repression, Mol. Cell. Biol., 35, 3800, 10.1128/MCB.00512-15
Cheng, 2013, Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system, Cell Res., 23, 1163, 10.1038/cr.2013.122
Gilbert, 2014, Genome-scale CRISPR-mediated control of gene repression and activation, Cell, 159, 647, 10.1016/j.cell.2014.09.029
Tanenbaum, 2014, A protein-tagging system for signal amplification in gene expression and fluorescence imaging, Cell, 159, 635, 10.1016/j.cell.2014.09.039
Chavez, 2015, Highly efficient Cas9-mediated transcriptional programming, Nat. Methods, 12, 326, 10.1038/nmeth.3312
Konermann, 2015, Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature, 517, 583, 10.1038/nature14136
Peabody, 1993, The RNA binding site of bacteriophage MS2 coat protein, EMBO J., 12, 595, 10.1002/j.1460-2075.1993.tb05691.x
Chavez, 2016, Comparison of Cas9 activators in multiple species, Nat. Methods, 13, 563, 10.1038/nmeth.3871
Liao, 2017, In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation, Cell, 171, 1495, 10.1016/j.cell.2017.10.025
Kretzmann, 2019, Tumour suppression by targeted intravenous nonviral CRISPRa using dendritic polymers, Chem. Sci., 10, 7718, 10.1039/C9SC01432B
Matharu, 2019, CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency, Science, 363, eaau0629, 10.1126/science.aau0629
Smith, 2013, DNA methylation: roles in mammalian development, Nat. Rev. Genet., 14, 204, 10.1038/nrg3354
Wu, 2014, Reversing DNA methylation: mechanisms, genomics, and biological functions, Cell, 156, 45, 10.1016/j.cell.2013.12.019
Attwood, 2002, DNA methylation and the regulation of gene transcription, Cell. Mol. Life Sci., 59, 241, 10.1007/s00018-002-8420-z
Siddique, 2013, Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity, J. Mol. Biol., 425, 479, 10.1016/j.jmb.2012.11.038
Bernstein, 2015, TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts, J. Clin. Invest., 125, 1998, 10.1172/JCI77321
Vojta, 2016, Repurposing the CRISPR-Cas9 system for targeted DNA methylation, Nucleic Acids Res., 44, 5615, 10.1093/nar/gkw159
McDonald, 2016, Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation, Biol. Open, 5, 866, 10.1242/bio.019067
Liu, 2016, Editing DNA methylation in the mammalian genome, Cell, 167, 233, 10.1016/j.cell.2016.08.056
Amabile, 2016, Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing, Cell, 167, 219, 10.1016/j.cell.2016.09.006
Huang, 2017, DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A, Genome Biol., 18, 176, 10.1186/s13059-017-1306-z
Pflueger, 2018, A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs, Genome Res., 28, 1193, 10.1101/gr.233049.117
Stepper, 2017, Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase, Nucleic Acids Res., 45, 1703, 10.1093/nar/gkw1112
Galonska, 2018, Genome-wide tracking of dCas9-methyltransferase footprints, Nat. Commun., 9, 597, 10.1038/s41467-017-02708-5
Lin, 2018, Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases, Gigascience, 7, 1, 10.1093/gigascience/giy011
Xiong, 2017, Targeted DNA methylation in human cells using engineered dCas9-methyltransferases, Sci. Rep., 7, 6732, 10.1038/s41598-017-06757-0
Lei, 2017, Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein, Nat. Commun., 8, 16026, 10.1038/ncomms16026
Maeder, 2013, Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins, Nat. Biotechnol., 31, 1137, 10.1038/nbt.2726
Choudhury, 2016, CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter, Oncotarget, 7, 46545, 10.18632/oncotarget.10234
Morita, 2016, Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions, Nat. Biotechnol., 34, 1060, 10.1038/nbt.3658
Xu, 2016, A CRISPR-based approach for targeted DNA demethylation, Cell Discov., 2, 16009, 10.1038/celldisc.2016.9
Gu, 2018, DNMT3A and TET1 cooperate to regulate promoter epigenetic landscapes in mouse embryonic stem cells, Genome Biol., 19, 88, 10.1186/s13059-018-1464-7
Bannister, 2011, Regulation of chromatin by histone modifications, Cell Res., 21, 381, 10.1038/cr.2011.22
Hilton, 2015, Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers, Nat. Biotechnol., 33, 510, 10.1038/nbt.3199
Kwon, 2017, Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC, Nat. Commun., 8, 15315, 10.1038/ncomms15315
Shi, 2004, Histone demethylation mediated by the nuclear amine oxidase homolog LSD1, Cell, 119, 941, 10.1016/j.cell.2004.12.012
Whyte, 2012, Enhancer decommissioning by LSD1 during embryonic stem cell differentiation, Nature, 482, 221, 10.1038/nature10805
Martin, 2005, The diverse functions of histone lysine methylation, Nat. Rev. Mol. Cell Biol., 6, 838, 10.1038/nrm1761
Mendenhall, 2013, Locus-specific editing of histone modifications at endogenous enhancers, Nat. Biotechnol., 31, 1133, 10.1038/nbt.2701
Kearns, 2015, Functional annotation of native enhancers with a Cas9-histone demethylase fusion, Nat. Methods, 12, 401, 10.1038/nmeth.3325
Wu, 2013, Molecular basis for the regulation of the H3K4 methyltransferase activity of PRDM9, Cell Rep., 5, 13, 10.1016/j.celrep.2013.08.035
Cano-Rodriguez, 2016, Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner, Nat. Commun., 7, 12284, 10.1038/ncomms12284